← Fresenius Medical Care AG & Co. KGaA overview

Fresenius Medical Care AG & Co. KGaA vs DaVita HealthCare Partners: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Fresenius Medical Care AG & Co. KGaA (FME.XETRA)

Q3 2026
▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

  • Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.

    This is the core financial result that directly drives investor confidence and the stock's valuation.

  • New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.

    New products and clinical evidence can open new markets and increase demand for the company's treatments.

  • China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.

    The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.

  • CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.

    A CEO change is a major event that can affect investor sentiment and future strategy.

August 2026
▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

  • Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.

    This is the core financial result that directly drives investor confidence and the stock's valuation.

  • New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.

    New products and clinical evidence can open new markets and increase demand for the company's treatments.

  • China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.

    The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.

  • CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.

    A CEO change is a major event that can affect investor sentiment and future strategy.

Latest
▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

  • Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.

    This is the core financial result that directly drives investor confidence and the stock's valuation.

  • New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.

    New products and clinical evidence can open new markets and increase demand for the company's treatments.

  • China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.

    The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.

  • CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.

    A CEO change is a major event that can affect investor sentiment and future strategy.

DaVita HealthCare Partners Inc (DVA)

Q3 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

July 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Latest
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.